Article
Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.
Current problems in cancer - 1 Jun 2025
Yamaguchi Yoh, Shinno Yuki, Masuda Ken, Ariyasu Ryo, Nosaki Kaname, Hakozaki Taiki, Tokito Takaaki, Nomura Shogo, Nishio Makoto, Goto Koichi, Hosomi Yukio, Azuma Koichi, Ohe Yuichiro
Abstract excerpt
BACKGROUND: Non-small cell lung cancer (NSCLC) with driver mutations, notably epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase, shows reduced sensitivity to immune checkpoint inhibitors. A subgroup analysis of the IMpower150 data on patients resistant to EGFR tyrosine kinase inhibitors (EGFR-TKI) before enrollment demonstrated prolonged progression-free survival (PFS) with atezolizumab,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.